1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Pfizer Inc.

Pfizer Inc.

PFE
Pfizer Inc.US flagNew York Stock Exchange
27.05
USD
+0.29
- -
154.17BMarket Cap
Pfizer Inc.
PFE
(New York Stock Exchange)

Recent

price

27.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.11
7.81
7.34
7.57
7.82
7.91
8.68
8.8
6.95
7.35
7.5
14.51
18.04
10.55
11.23
11.01
11.19
Revenue per Share
1.03
1.28
1.96
3.23
1.44
1.13
1.18
3.57
1.9
2.88
1.65
3.92
5.59
0.38
1.42
1.37
0.76
Basic EPS, GAAP
1.24
2.35
2.06
2.38
2.44
2.14
2.33
2.44
2.33
1.82
2.1
5.33
4.64
0.85
1.74
1.6
1.93
Free Cash Flow per Basic Share
0.76
0.8
0.88
0.97
1.04
1.12
1.2
1.28
1.36
1.44
1.52
1.56
1.6
1.64
1.68
1.72
1.72
Dividend per Share
10.95
10.84
11.16
11.92
11.33
10.48
9.81
11.92
11.09
11.41
11.36
13.74
17.03
15.77
15.56
15.21
14.95
Book Value per Share
-1.72
-1.8
-1.04
-0.88
-0.95
-3.87
-7.84
-5.59
-4.41
-3.44
-2.63
0.51
0.16
-7.73
-6.31
-6.77
-5.84
Tangible Book Value per Share
8,036
7,817
7,442
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,608
5,643
5,664
5,683
5,690
Basic Weighted Avg Shares
65,165
61,035
54,657
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,695
Sales/Revenue/Turnover
25.41
27.54
31.24
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
26.72
Operating Margin (%)
8,399
9,026
7,655
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,584
Depreciation Expense
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
4,332
Net Income, GAAP
12.17
31.54
19.76
27.4
25.49
22.2
13.45
- -
19.64
5.15
5.26
7.62
9.58
- -
- -
- -
14.54
Effective Tax Rate (%)
12.67
16.4
26.66
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
6.8
Profit Margin (%)
31,859
31,908
35,645
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
8,712
Working Capital
38,410
34,926
31,036
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
60,495
LT Debt
88,265
82,621
81,678
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
85,492
Total Equity
9.82
9
11.32
10.19
9.07
9.57
11.67
- -
4.92
6.29
8.3
20.13
27.89
- -
- -
- -
- -
Return on Invested Capital (%)
7.22
8.76
13.1
19.77
9.14
7.46
8.07
- -
11.1
15.95
9.72
21.39
26.47
- -
- -
- -
5.9
Return on Capital (%)
9.29
11.78
17.83
27.94
12.38
10.24
11.62
32.58
16.56
25.33
14.5
31.3
36.3
2.29
9.06
8.9
4.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,154
3,890
2,699
LT Borrowings
60,807
59,840
60,495
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,686
5,699
5,699
Market Capitalization
141,581
160,028
137,243

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
42,898
42,822
41,358
Cash, Cash Equivalents & STI
13,596
13,075
11,698
Accounts Receivable, Net
11,874
12,585
12,490
Inventories
10,654
10,667
9,945
Total Current Liabilities
36,984
34,348
32,646
Payables & Accruals
10,788
7,636
7,685
ST Debt
3,154
3,890
2,699
Deferred Revenue
784
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
15,034
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.01
0.79
0.07
1.42
2025
0.52
0.51
0.62
-0.29
1.37
2026
0.47
-0.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.42
0.42
0.42
1.68
2025
0.43
0.43
0.43
0.43
1.72
2026
0.43
0.43
- -
- -
- -
Similar Companies
Sanofi (SNYNF)
Nissui Pharmaceutical Co., Ltd. (4550.T)
PT Kalbe Farma Tbk. (KLBF.JK)
AbbVie Inc. (ABBV.BA)
AstraZeneca PLC (AZN.ST)
Biogen Inc. (IDP.DE)
Business
Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.

Company News

APIChatGPT

  • zacks.com

    Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

  • fool.com

    Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

  • finbold.com

    Monster insider trading alert for Pfizer stock

  • 247wallst.com

    After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

  • seekingalpha.com

    Pfizer: Q2 Strength Overshadows Obesity Setbacks

  • 247wallst.com

    Boomers Should Buy These High-Yield Dividend August Bargains Hand-Over-Fist

  • zacks.com

    Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts

  • marketbeat.com

    Pfizer Q2 Earnings Call Highlights

  • seekingalpha.com

    Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript

  • zacks.com

    PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut

  • zacks.com

    Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics

  • proactiveinvestors.com

    Pfizer raises revenue outlook after quarterly earnings top estimates

  • benzinga.com

    Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings

  • zacks.com

    Pfizer (PFE) Q2 Earnings and Revenues Top Estimates

  • wsj.com

    Pfizer Post Loss on Higher Revenue

  • cnbc.com

    Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

  • barrons.com

    Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

  • reuters.com

    Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

  • businesswire.com

    Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

  • benzinga.com

    Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday